Evidence map›Paper›PMID 40130908›Full record

ArticleActa neuropsychiatrica2025

Influence of CYP2D6 phenotype on adherence, adverse effects, and attitudes in aripiprazole and risperidone users.

Elina Hietala, Anssi Solismaa, Markku Lähteenvuo, Ari V Ahola-Olli, Katja Häkkinen, Kimmo Suokas, Erkki Isometsä, Jaana Suvisaari, Tuula Kieseppä, Minna Holm and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropsychiatrica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Elina HietalaFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.ORCID https://orcid.org/0000-0003-2001-4322
Anssi SolismaaFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Markku LähteenvuoDepartment of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
Ari V Ahola-OlliInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
Katja HäkkinenDepartment of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
Kimmo SuokasFaculty of Social Sciences, Tampere University, Tampere, Finland.
Erkki IsometsäDepartment of Psychiatry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Jaana SuvisaariMental Health Team, Finnish Institute for Health and Welfare, Helsinki, Finland.
Tuula KieseppäHospital District of Helsinki and Uusimaa, Helsinki, Finland.
Minna HolmMental Health Team, Finnish Institute for Health and Welfare, Helsinki, Finland.
Jari TiihonenDepartment of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
Jouko LönnqvistFinnish Institute for Health and Welfare (THL), Helsinki, Finland.
Jarmo HietalaUniversity of Turku, Faculty of Medicine, Department of Clinical Medicine (Psychiatry), Turku, Finland.
Asko WegeliusDepartment of Psychiatry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Kaisla LahdensuoMehiläinen, Helsinki, Finland.
Willehard HaakiUniversity of Turku, Faculty of Medicine, Department of Clinical Medicine (Psychiatry), Turku, Finland.
study SUPER-Finland
Olli KampmanFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.ORCID https://orcid.org/0000-0001-6891-2266

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-adherence and negative attitudes towards medication are major problems in treating psychotic disorders. Cytochrome P450 2D6 (CYP2D6) contributes to the metabolism of aripiprazole and risperidone, and variations in CYP2D6 activity may affect treatment response or adverse effects. However, the impact of these variations on adherence and medication attitudes is unclear. This study investigates the relationships between CYP2D6 phenotype, self-reported adherence, adverse effects, and attitudes among aripiprazole and risperidone users. The study analysed data from the SUPER-Finland cohort of 10,474 adults with psychotic episodes, including 1,429 aripiprazole and 828 risperidone users. The Attitudes towards Neuroleptic Treatment (ANT) questionnaire assessed adherence and adverse effects in all patients, while medication-related attitudes were examined in a subgroup of 1,000 participants. Associations between CYP2D6 phenotypes and outcomes were analysed using logistic regression and beta regression in aripiprazole and risperidone groups separately. Among risperidone users, we observed no association between CYP2D6 phenotypes and adherence, adverse effects, or attitudes. Similarly, we found no link between adherence and CYP2D6 phenotypes among aripiprazole users. However, aripiprazole users with the ultrarapid CYP2D6 phenotype had more adverse effects (OR = 1.71, 95 % CI 1.03–2.90,

Indexed as

Antipsychotic AgentsAripiprazoleCytochrome P-450 CYP2D6Medication AdherencePsychotic DisordersRisperidoneAdultAttitude to HealthCohort StudiesFemaleFinlandHumansLogistic ModelsMaleMiddle AgedPhenotypeAntipsychotic AgentsAripiprazoleCYP2D6 protein, humanCytochrome P-450 CYP2D6Risperidoneantipsychotic agentscytochrome P-450 CYP2D6pharmacogeneticsPsychotic disorderstreatment adherence and compliance

Identifiers

PMID40130908
PMCPMC13130289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.